Elicio Therapeutics, Inc. (ELTX)
| Market Cap | 76.29M -39.8% |
| Revenue (ttm) | n/a |
| Net Income | -40.19M |
| EPS | -2.42 |
| Shares Out | 19.07M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,188,552 |
| Open | 3.720 |
| Previous Close | 3.750 |
| Day's Range | 3.629 - 4.100 |
| 52-Week Range | 2.660 - 16.000 |
| Beta | 1.44 |
| Analysts | Buy |
| Price Target | 20.67 (+416.75%) |
| Earnings Date | Aug 6, 2026 |
About ELTX
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node-targeted AMP peptide treatment for mutant b-raf murine sarcoma viral oncogene homolog B1-(BRAF) driven cancers, and ELI-008, a multivalent lymph node-targe... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for ELTX stock is "Buy." The 12-month stock price target is $20.67, which is an increase of 416.75% from the latest price.
News
Elicio Therapeutics Transcript: KOL event
Experts presented rare complete responses in metastatic KRAS-mutated pancreatic cancer after ELI-002 and checkpoint inhibitor therapy, supported by translational data showing durable, polyfunctional T cell responses and antigen spreading. A staged clinical development plan is underway to validate these findings in prospective trials.
Elicio Therapeutics assumed with a Buy at Ladenburg
Ladenburg assumed coverage of Elicio Therapeutics (ELTX) with a Buy rating and $12 price target The firm views the selloff post the Phase II ELI-002 data as overblown. The ELI-002…
Elicio Therapeutics reports complete responses in pancreatic cancer trial
Elicio Therapeutics (ELTX) reported preliminary clinical observations from its recently completed Phase 2 AMPLIFY-7P study of its cancer immunotherapy, ELI-002 7P. Three patients who experienced disea...
Elicio Therapeutics Reports Multiple Complete Responses After ELI-002 7P Treatment and Subsequent Therapy with Checkpoint Inhibition in Metastatic mKRAS Pancreatic Cancer
100% confirmed complete radiographic and complete metabolic responses in three patients who progressed on ELI-002 7P treatment during the Phase 2 AMPLIFY-7P study and received nivolumab-based subseque...
Elicio Therapeutics Investigation Initiated: SueWallSt Investigates the Officers and Directors of Elicio Therapeutics (ELTX)
Elicio Therapeutics reported Q1 2026 results showing a widening net loss and zero revenue days before its lead clinical program failed -- investors who bought ELTX lost 72.5% in a single session. NEW ...
Elicio Therapeutics downgraded to Hold from Buy at JonesResearch
JonesResearch downgraded Elicio Therapeutics (ELTX) to Hold from Buy without a price target The company’s Phase IIb trial failed to show a significant reduction in disease-free survival with ELI-002 7...
Elicio shares tumble after pancreatic cancer therapy misses mid-stage study goal
Elicio Therapeutics shares fell about 73% in early trading on Monday after the biotech firm's pancreatic cancer therapy failed to significantly extend the time patients lived without their disease re...
Elicio selloff brings attractive entry point, says H.C. Wainwright
H.C. Wainwright views the selloff today in shares of Elicio Therapeutics (ELTX) as an attractive entry point for investors. The company presented findings supporting the hypothesis that extending trea...
Elicio Therapeutics Transcript: Study update
AMPLIFY-7P phase II did not meet its primary endpoint but showed a strong treatment effect and immune response in R0 resected pancreatic cancer patients, informing a precision medicine phase III strategy focused on this group and extended dosing. The safety profile was favorable, and broader applications in KRAS-driven cancers are anticipated.
Elicio Therapeutics Slides: Study update
Elicio Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on June 15, 2026.
Elicio Therapeutics Press release: Study update
Elicio Therapeutics issued a press release on June 15, 2026, disclosing material business information to investors.
Elicio Therapeutics price target raised to $23 from $17 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Elicio Therapeutics (ELTX) to $23 from $17 and keeps a Buy rating on the shares after the company announced that ELI-002 7P…
Elicio Therapeutics reports AMPLIFY-7P study did not meet primary endpoint
Elicio Therapeutics (ELTX) reported results from its randomized Phase 2 AMPLIFY-7P study evaluating ELI-002 7P in patients with adjuvant mKRAS-driven pancreatic ductal adenocarcinoma following complet...
Elicio Therapeutics Reports Results from Phase 2 AMPLIFY-7P Study and Outlines Refined Phase 3 Development Strategy for ELI-002 7P in Adjuvant Pancreatic Cancer
BOSTON, June 15, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for mKR...
Elicio Therapeutics initiated with a Buy at B. Riley
B. Riley initiated coverage of Elicio Therapeutics (ELTX) with a Buy rating and $27 price target Elicio’s off-the-shelf mKRAS vaccine in adjuvant pancreatic cancer is the only randomized mKRAS-targete...
Elicio Therapeutics publishes data on AMP-DNA adjuvant technology
Elicio Therapeutics (ELTX) announced the publication of a peer-reviewed manuscript in Science Advances describing a series of novel AMP-DNA adjuvant candidates built from the lymph node-targeting Amph...
Elicio Therapeutics Announces Publication in Peer-Reviewed Journal Science Advances Highlighting Potent and Durable Immune Responses Driven by Company's AMP-DNA Adjuvant Technology
BOSTON, June 01, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for...
Elicio Therapeutics Transcript: Bank of America Global Healthcare Conference 2026
The AMP platform is advancing immunotherapeutics targeting KRAS and other mutations, with ELI-002 showing robust immune responses and improved survival in early trials. Phase II results in adjuvant pancreatic cancer are expected mid-2026, with strong financial support for ongoing development.
Elicio Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates
In the ongoing Phase 2 AMPLIFY-7P study evaluating ELI-002 7P in patients with pancreatic ductal adenocarcinoma (“PDAC”), the event-driven primary disease-free survival (“DFS”) analysis is anticipated...
Elicio Therapeutics Earnings release: Q1 2026
Elicio Therapeutics released its Q1 2026 earnings on May 11, 2026, summarizing the period's financial results.
Elicio Therapeutics Quarterly report: Q1 2026
Elicio Therapeutics has published its Q1 2026 quarterly earnings report on May 11, 2026.
Elicio Therapeutics to Present at the Bank of America Healthcare Conference
BOSTON, April 30, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies fo...
Elicio Therapeutics Reports Inducement Grants
BOSTON, April 16, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies fo...
Elicio Therapeutics initiated with a Buy at Ladenburg
Ladenburg initiated coverage of Elicio Therapeutics (ELTX) with a Buy rating and $20 price target The firm says the company is creating the new standard of care in minimal residual…
Elicio Therapeutics price target raised to $17 from $13 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Elicio Therapeutics (ELTX) to $17 from $13 and keeps a Buy rating on the shares. To reflect the data seen to date,…